



Metal-Based Nanoparticles: New Insights into Cancer Diagnosis and Therapy

Guest Editors:

Prof. Dr. Sophie Laurent

1. Department of General, Organic and Biomedical Chemistry, NMR and Molecular Imaging Laboratory, University of Mons, B-7000 Mons, Belgium
2. Center for Microscopy and Molecular Imaging, Rue Adrienne Bolland, 8, B-6041 Gosselies, Belgium

Dr. Sébastien Penninckx

1. Radiotherapy department, Jules Bordet Institute, Rue Héger – Bordet 1, B-1000 Brussel, Belgium
2. Research Center for the Physics of Matter and Radiation (PMR-LARN), Namur Research Institute For Life Sciences (NARILIS), University of Namur, Rue de Bruxelles 61, B-5000 Namur, Belgium

Message from the Guest Editors

In recent decades, the development of nanomedicine has offered the possibility to take advantage of nanoscale materials to improve cancer management. Studies have demonstrated the ability of metallic nanoparticles to improve the performance of imaging techniques and to enhance the effects of various treatment modalities (radiotherapy, chemotherapy, immunotherapy, etc.). In synergy, these two properties make these nano-objects potential theranostic agents able to image and provide therapeutic benefit. Therefore, cancer nanomedicine has become one of the leading areas of promise, with first-generation nano-objects reaching the level of clinical trials. Recently, multidisciplinary insights into the interaction of metal-based nanoparticles with cellular systems have advanced, paving the way for new combination therapies and the development of the next generation of nano-objects.

Deadline for manuscript
submissions:

closed (30 September 2022)



mdpi.com/si/92744

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma